EMEA-002468-PIP04-18
Key facts
| Active substance |
belantamab mafodotin
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0347/2019
|
| PIP number |
EMEA-002468-PIP04-18
|
| Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of Multiple Myeloma
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
GlaxoSmithKline Trading Services Limited
Tel. +44 (0)20 8990 3836 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions/indications
|